WO2004063335A3 - TNF-α BINDING MOLECULES - Google Patents

TNF-α BINDING MOLECULES Download PDF

Info

Publication number
WO2004063335A3
WO2004063335A3 PCT/US2004/000290 US2004000290W WO2004063335A3 WO 2004063335 A3 WO2004063335 A3 WO 2004063335A3 US 2004000290 W US2004000290 W US 2004000290W WO 2004063335 A3 WO2004063335 A3 WO 2004063335A3
Authority
WO
WIPO (PCT)
Prior art keywords
tnf
binding molecules
present
human
relates
Prior art date
Application number
PCT/US2004/000290
Other languages
French (fr)
Other versions
WO2004063335A2 (en
Inventor
Jeffry D Watkins
Alain P Vasserot
David Marquis
William D Huse
Original Assignee
Applied Molecular Evolution
Jeffry D Watkins
Alain P Vasserot
David Marquis
William D Huse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/338,627 external-priority patent/US20040131613A1/en
Priority claimed from US10/338,552 external-priority patent/US7101978B2/en
Application filed by Applied Molecular Evolution, Jeffry D Watkins, Alain P Vasserot, David Marquis, William D Huse filed Critical Applied Molecular Evolution
Priority to EP04700833A priority Critical patent/EP1590431A4/en
Priority to JP2006500817A priority patent/JP2007525409A/en
Priority to US10/541,260 priority patent/US7435799B2/en
Publication of WO2004063335A2 publication Critical patent/WO2004063335A2/en
Publication of WO2004063335A3 publication Critical patent/WO2004063335A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to TNF-α binding molecules and nucleic acid sequences encoding TNF-α binding molecules. In particular, the present invention relates to TNF-α binding molecules with a high binding affinity, a high association rate, a low dissociation rate with regard to human TNF-α and that are capable of neutralizing TNF-α at low concentrations. Preferably, the TNF-α binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).
PCT/US2004/000290 2003-01-08 2004-01-08 TNF-α BINDING MOLECULES WO2004063335A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04700833A EP1590431A4 (en) 2003-01-08 2004-01-08 TNF-a BINDING MOLECULES
JP2006500817A JP2007525409A (en) 2003-01-08 2004-01-08 TNF-α binding molecule
US10/541,260 US7435799B2 (en) 2004-01-08 2004-01-08 TNF-α binding molecules

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/338,552 2003-01-08
US10/338,627 US20040131613A1 (en) 2003-01-08 2003-01-08 TNF-alpha binding molecules
US10/338,552 US7101978B2 (en) 2003-01-08 2003-01-08 TNF-α binding molecules
US10/338,627 2003-01-08

Publications (2)

Publication Number Publication Date
WO2004063335A2 WO2004063335A2 (en) 2004-07-29
WO2004063335A3 true WO2004063335A3 (en) 2009-06-04

Family

ID=32716888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/000290 WO2004063335A2 (en) 2003-01-08 2004-01-08 TNF-α BINDING MOLECULES

Country Status (3)

Country Link
EP (1) EP1590431A4 (en)
JP (1) JP2007525409A (en)
WO (1) WO2004063335A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
CN102127167B (en) * 2010-01-15 2013-06-19 苏州工业园区晨健抗体组药物开发有限公司 Whole human TNF alpha (tumor necrosis factor alpha) monoclonal antibody and preparation and application thereof
CN102336834B (en) * 2010-07-22 2014-01-01 苏州工业园区晨健抗体组药物开发有限公司 Fully human TNFalpha-Fab antibody and its PEG antibody
US9803009B2 (en) 2011-10-24 2017-10-31 Abbvie Inc. Immunobinders directed against TNF

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
DK0929578T3 (en) * 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Human antibodies that bind human TNFalfa

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARNES ET AL.: "Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases.", N ENGL J MED., vol. 336, no. 15, April 1997 (1997-04-01), pages 1066 - 1071, XP002504200 *
BODER ET AL.: "Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity.", PROC NATL ACAD SCI USA., vol. 97, no. 20, September 2000 (2000-09-01), pages 10701 - 10705, XP002185398 *
GAVILONDO ET AL.: "Antibody engineering at the millennium.", BIOTECHNIQUES., vol. 29, no. I, July 2000 (2000-07-01), pages 128 - 149, XP000990322 *
See also references of EP1590431A4 *

Also Published As

Publication number Publication date
EP1590431A4 (en) 2009-12-23
JP2007525409A (en) 2007-09-06
WO2004063335A2 (en) 2004-07-29
EP1590431A2 (en) 2005-11-02

Similar Documents

Publication Publication Date Title
TW200509969A (en) CD20 binding molecules
WO2005118644A3 (en) Binding molecules capable of neutralizing rabies virus and uses thereof
NO20171697A1 (en) IL-17 Antagonistic Antibodies
WO2005047314A3 (en) Fgf-beta binding and supported peptides
WO2005047471A3 (en) Improved fret efficiency methods
WO2005014850A3 (en) Systems and methods for analyzing nucleic acid sequences
WO2008079246A3 (en) Cd44 antibodies
RS28904A (en) Angiopoietin-2 specific binding agents
IL184498A0 (en) Antigen binding molecules that bind egfr, vectors encoding same , and uses thereof
WO2006067122A3 (en) Binding molecules capable of neutralizing west nile virus and uses thereof
WO2009004066A3 (en) Providing improved immunoglobulin sequences by mutating cdr and/or fr positions
MX2007004247A (en) Angiopoietin-2 specific binding agents.
WO2006068975A3 (en) Binding proteins specific for human matriptase
WO2005041896A3 (en) Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke
WO2005025515A3 (en) Proteasome pathway inhibitors and related methods
WO2005054438A3 (en) Nucleic acid molecules containing recombination sites and methods of using the same
WO2004063335A3 (en) TNF-α BINDING MOLECULES
WO2005077397A3 (en) Methods and compositions for treating vascular diseases
WO2004101608A3 (en) Apo2l (trail) receptor binding peptides and uses thereof
WO2001066752A3 (en) Reproduction-specific genes
WO2005047325A3 (en) Monkey immunoglobulin sequences
WO2004067569A8 (en) Internalising human binding molecules against cd72
WO2005017177A3 (en) Modulators of nod1 signaling
WO2005019252A8 (en) Novel fluorescent and colored proteins, and polynucleotides that encode these proteins
WO2007035518A3 (en) Aptamers as agonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006269549

Country of ref document: US

Ref document number: 10541260

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006500817

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2004700833

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004700833

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10541260

Country of ref document: US